Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2020 · 10-Q
Revenue$192.50M$192.50M+1.0% vs Q1 2019 Net Income-$12.50M-$12.50MN/M vs Q1 2019 EPS Diluted-$0.24-$0.24N/M vs Q1 2019 Operating Income-$11,600,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Free Cash Flowderived$33,600,000−59.7% Margins · derivedOperating margin-6.0%+8.3 pt vs Q1 2019
Net margin-6.5%+7.2 pt vs Q1 2019
ended Mar 31, 2020 · filed May 1, 2020 · 31 d after period end